StreetInsider.com News Articles

Rua Bioscience and PharmAla Biotech partner to supply medicinal MDMA in New Zealand

Thu, 08 Oct 2026 16:15:00 -0400

TAIRĀWHITI, New Zealand and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Rua Bioscience Limited (NZX: RUA) (“Rua”) and PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) (“PharmAla”) announce that Rua and PharmAla Biotech Inc., a subsidiary of PharmAla, have signed a distribution and licence agreement. Under the agreement, Rua will import, distribute and sell PharmAla’s pharmaceutical-grade LaNeo™ MDMA in New Zealand.

The agreement follows Medsafe’s approval, on 4 September 2026, of two psychiatrists to prescribe pharmaceutical-grade MDMA for post-traumatic stress disorder (PTSD). This makes New Zealand only the second country, after Australia, to allow authorised psychiatrists to

Rua Bioscience and PharmAla Biotech partner to supply medicinal MDMA in New Zealand

Thu, 08 Oct 2026 16:15:00 -0400

PharmAla Biotech Provides Corporate Update: Change of Auditor, Retention of Watertower Research and Oak Hill

Thu, 17 Sep 2026 08:30:00 -0400

TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), today announced three corporate updates.

1. Change of Auditor:

The Company determined that it was in its future best interest to pursue engaging an auditor who is capable of conducting a U.S. Public Company Accounting Oversight Board (“PCAOB”) mandate. The mandate was offered to Clearhouse LLP (the “Predecessor Auditor”), which advised the Company that it was unable

PharmAla Biotech Provides Corporate Update: Change of Auditor, Retention of Watertower Research and Oak Hill

Thu, 17 Sep 2026 08:30:00 -0400

1. Change of Auditor:

PharmAla Biotech Provides Corporate Update: Change of Auditor, Retention of Watertower Research and Oak Hill

Thu, 17 Sep 2026 08:30:00 -0400

1. Change of Auditor:

PharmAla Biotech Provides Corporate Update: Change of Auditor, Retention of Watertower Research and Oak Hill

Thu, 17 Sep 2026 08:30:00 -0400

1. Change of Auditor:

PharmAla Issues Q3 Financial Statements and AGM Update

Thu, 30 Jul 2026 07:30:00 -0400

TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended February 28, 2026. All figures are reported in Canadian dollars. The Company’s full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at

PharmAla Issues Q3 Financial Statements and AGM Update

Thu, 30 Jul 2026 07:30:00 -0400

PharmAla Issues Q3 Financial Statements and AGM Update

Thu, 30 Jul 2026 07:30:00 -0400

PharmAla Issues Q3 Financial Statements and AGM Update

Thu, 30 Jul 2026 07:30:00 -0400

PharmAla Issues Q3 Financial Statements and AGM Update

Thu, 30 Jul 2026 07:30:00 -0400

PharmAla Issues Q3 Financial Statements and AGM Update

Thu, 30 Jul 2026 07:30:00 -0400

PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset

Mon, 06 Jul 2026 08:15:00 -0400

TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced the successful completion of GMP (Good Manufacturing Practice) manufacturing of drug substance necessary for the manufacturing of ALA-002. This milestone marks a significant step forward in the program’s development, providing sufficient material to support upcoming clinical activities.